Table 3.

Association of Cardiology Care to Mortality and Adverse Events in Newly-Diagnosed AF

	Full Cohort				Propensity Matched Cohort
	Univariate		Multivariate*
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Stroke	0.86 (0.82–0.91)	<0.0001	0.91 (0.86–0.96)	0.001	0.88 (0.83–0.94)	0.0003
Overall Mortality	0.82 (0.81–0.84)	<0.0001	0.89 (0.88–0.91)	<0.0001	0.90 (0.88–0.92)	<0.0001
Cardiovascular mortality†	0.82 (0.79–0.85)	<0.0001	0.88 (0.84–0.91)	<0.0001	0.90 (0.86–0.94)	<0.0001
TIA	0.99 (0.87–0.93)	0.87	0.95 (0.87–1.04)	0.27	0.99 (0.89–1.10)	0.88
Heart Failure	1.18 (1.16–1.21)	<0.0001	1.02 (1.00–1.05)	0.088	1.07 (1.04–1.10)	<0.0001
AF/SVT	1.71 (1.67–1.74)	<0.0001	1.38 (1.35–1.42)	<0.0001	1.44 (1.41–1.48)	<0.0001
Myocardial Infarction	1.23 (1.20–1.26)	<0.0001	1.03 (1.00–1.05)	0.04	1.08 (1.05–1.11)	<0.0001

AF: atrial fibrillation, HR: hazard ratio, SVT: supraventricular tachycardia), TIA: transient ischemic attack

^*Multivariate model includes: demographics (age, patient distance to clinic/medical center, race, sex, and VA priority status), comorbidities (Charlson comorbidity index, diabetes, heart failure, hypertension, Selim comorbidity index, stroke/transient ischemic attack, and glomerular filtration rate), non AF medications (antiplatelet, ACE inhibitor/angiotensin receptor blocker, diuretics, niacin/fibrates, and statins), and AF medications (amiodarone, anticoagulation [warfarin/novel oral anticoagulant], beta blockers, calcium channel blockers, class I agents, class III agents, digoxin),

^†Death preceded by cardiovascular hospitalization within 30 days